By Kamal Choudhury and Mariam Sunny Jan 20 (Reuters) - Moderna and Merck said on Tuesday their experimental personalized ...

In a small clinical trial, customized mRNA vaccines against high-risk skin cancers appeared to reduce the risk of cancer recurrence and death by nearly 50 percent over five years when compared with ...

In patients with high-risk melanoma, the personalized cancer vaccine intismeran autogene and Keytruda reduced the risk of ...

The five-year results come from a phase 2b study that tested intismeran autogene in combination with Merck’s Keytruda in ...

Moderna and Merck shared five-year study data showing their combined cancer treatment cut the risk of melanoma coming back or ...

A combination of intismeran autogene and Keytruda significantly prolonged recurrence-free survival in melanoma.

A personalised mRNA vaccine developed by Moderna and Merck shows lasting benefits for patients with high-risk skin cancer.

Earlier this week, Merck and Moderna, two pharmaceutical companies specializing in vaccines, released statements about their collaborative efforts to devel | Cancer ...

Shares of Moderna MRNA were up 15.8% on Jan. 21, after the company and its partner Merck MRK announced positive median ...

New personalized skin cancer treatment shows success in preventing return of high-risk melanoma - Patients with severe ...

The second annual report from the National Cancer Database (NCDB) of the American College of Surgeons (ACS) documents a ...

Israel Cancer Research Fund (ICRF) and the Cancer Research Institute (CRI) have partnered on a new award, the ICRF-CRI Immunotherapy Collaborative Project Grant, given to Dr. Asaf Madi, PhD, of Tel ...